Status:
COMPLETED
Distinction Risk of Severe Infection in Febrile Neutropenia After Chemotherapy
Lead Sponsor:
University Hospital, Lille
Collaborating Sponsors:
Ministry of Health, France
Ligue contre le cancer, France
Conditions:
Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy
Eligibility:
All Genders
1-18 years
Brief Summary
Evaluate the reproducibility and validate a posteriori a new rule of clinical decision on a multi-center population of children with a post-chemotherapy febrile neutropenia
Eligibility Criteria
Inclusion
- Child aged 1 to 18 years
- Child with hematology or cancer
- Child with a febrile neutropenia post-chemotherapy
- Child with social security
- No opposition from the child and/or parents, in case of absence, the holder of the parental authority present, can consent, alone, to the participation of the unemancipated minor.
Exclusion
- Febrile neutropenia at diagnosis of tumor disease
- Child with palliative care
- Child having had a hematopoietic stem cell allo-graft in the preceding year
- Febrile neutropenia immediately post auto-transplant
- Antibiotherapy prior to admission
- Initial care in a non-investigative center.
Key Trial Info
Start Date :
May 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2017
Estimated Enrollment :
1900 Patients enrolled
Trial Details
Trial ID
NCT03434795
Start Date
May 1 2012
End Date
May 1 2017
Last Update
February 15 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Jeanne de Flandre - CHRU de Lille
Lille, France